Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q3 2014 · 10-Q
Revenue$176.55M$176.55M+29.0% vs Q3 2013 Net Income$7.45M$7.45MN/M vs Q3 2013 EPS Diluted$0.05$0.05N/M vs Q3 2013 Operating Income$11,203,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$33,727,000N/M Margins · derivedOperating margin6.3%+43.4 pt vs Q3 2013
Net margin4.2%+43.0 pt vs Q3 2013
ended Sep 30, 2014 · filed Oct 28, 2014 · 28 d after period end